Abaloparatide (brand name Tymlos) is a synthetic prescription medication used to treat postmenopausal women and men with osteoporosis at high risk for fractures, specifically those with a history of fractures or multiple risk factors.
It is an anabolic agent administered via a once-daily, self-injected subcutaneous shot.
Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP).
It stimulates new bone formation and increasing bone mineral density (BMD), making bones less likely to break.
Indications: Approved for high-risk postmenopausal women and men with osteoporosis, including those who have failed or are intolerant to other therapies.
It is a daily, self-administered subcutaneous injection, typically into the periumbilical region of the abdomen.
Treatment Duration: It is generally used for up to 18–24 months.
It significantly reduces the risk of vertebral and nonvertebral fractures in postmenopausal women.
Risk of Osteosarcoma: Abaloparatide caused a dose-dependent increase in osteosarcoma (a type of bone cancer) in animal studies.
It is unknown if this affects humans, but it is not recommended for patients at an increased risk of osteosarcoma-those with Paget’s disease or unexplained elevated alkaline phosphatase).
Bone Density Limits: Cumulative use with other parathyroid hormone analogs should not exceed 2 years total.
Common Side Effects: These include hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, vertigo, and abdominal pain.
Common osteoporosis drugs (like bisphosphonates) stop bone loss (anti-resorptive), abaloparatide builds new bone (anabolic).
It may provide superior reduction in vertebral fracture risk compared to alendronate.